3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
9
Melanoma
4
Neoplasms
3
Multiple Myeloma
3
Skin Neoplasms
2
Polycystic Ovary Syndrome
2
Venous Thromboembolism
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Renal Insufficiency
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Obesity
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Meningioma
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, B-Cell
1
Leukemia
1
Inflammation
1
Interventions
fludarabine phosphate
16
Cyclophosphamide
15
Peripheral Blood Stem Cell Transplantation
10
Tacrolimus
9
Busulfan
9
Whole-Body Irradiation
8
Mycophenolic Acid
8
fludarabine
6
Methotrexate
6
Cyclosporine
6
Radiotherapy
5
ruxolitinib
4
Biopsy
4
Antilymphocyte Serum
4
Specimen Handling
3
Decitabine
3
peginterferon alfa-2a
2
givinostat hydrochloride
2
givinostat
2
bomedemstat
2
Stem Cell Transplantation
2
Prednisone
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
Methylprednisolone
2
Melphalan
2
Imatinib Mesylate
2
Filgrastim
2
Etoposide
2
Cytarabine
2
Aspirin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thrombocythemia, Essential
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled